NDA 020134 · Q Biomed
Metastron
Strontium Chloride Sr-89 · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 20, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jun 18, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 1993 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- METASTRON · STRONTIUM CHLORIDE SR-89 1mCi/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Strontium Chloride Sr-89" as an intervention, any sponsor and status, largest first.
- Artificial Oocyte Activation Comparing Tow Different AgentsPivotal-lookingCompleted
Ibn Sina HospitalGovernment (non-federal)
NCT02424214 · 450 participants · Start Apr 2015 · Primary completion Jan 2016
Drug: Ca Ionophore; Strontium Chloride · For: Oocyte Fertilization
Sites: Manama, Bahrain; Asyut, Egypt; Sohag, Egypt
- A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the KneePivotal-lookingStatus unknown
Smerud Medical Research International ASAcademic, hospital or other
NCT00954629 · 300 participants (planned) · Start Jun 2009 · Primary completion May 2010
Drug: strontium chloride hexahydrate; Placebo · For: Pain; Osteoarthritis
Sites: Helsinki, Finland; Kuopio, Finland; Turku, Finland · 15 sites in all
- Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone TherapyPivotal-lookingCompleted
University Hospital BirminghamAcademic, hospital or other
NCT00554918 · 300 participants (planned) · Start Feb 2005 · Primary completion Dec 2008
Drug: docetaxel; prednisolone and 1 more · For: Metastatic Cancer; Prostate Cancer
Sites: Birmingham, United Kingdom; Cheltenham, United Kingdom; Gloucester, United Kingdom · 16 sites in all
- Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate CancerPivotal-lookingTerminated
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00024167 · 265 participants · Start Apr 2002 · Primary completion Sep 2014
Drug: Docetaxel; Doxorubicin hydrochloride and 5 more · For: Prostate Cancer
Sites: Gainesville, Georgia; Savannah, Georgia; Hines, Illinois · 40 sites in all
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00365105 · 261 participants · Start Jul 11, 2006 · Primary completion Jan 2012
Drug: zoledronic acid; Sm-153 · For: Breast Cancer; Lung Cancer; Metastatic Cancer and 2 more
Sites: Mobile, Alabama; Burbank, California; Carmichael, California · 147 sites in all
- Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump PainPivotal-lookingStatus unknown
Smerud Medical Research International ASAcademic, hospital or other
NCT00804375 · 150 participants (planned) · Start Dec 2008 · Primary completion Jun 2010
Drug: 2PX; Placebo · For: Stump Pain
Sites: Aarhus, Denmark; Herlev, Denmark; Hvidovre, Denmark · 19 sites in all
- Effectiveness of a Homecare Dentin Hypersensitivity GelPivotal-lookingCompleted
Universidade Federal de Santa MariaAcademic, hospital or other
NCT02128633 · 126 participants · Start Nov 2009 · Primary completion Jun 2013
Drug: placebo gel; 5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% and 1 more · For: Dentin Sensitivity
Sites: Santa Maria, Brazil
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00081159 · 80 participants · Start Jul 2004 · Primary completion Sep 2014
Drug: Doxorubicin hydrochloride; Goserelin acetate and 2 more · For: Metastatic Cancer; Prostate Cancer
Sites: Orlando, Florida; Wichita, Kansas; Houston, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone.
McEwan AJ, Amyotte GA, McGowan DG, et al. · Nucl Med Commun 1994 · Clinical Trial, Comparative Study
- Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience.
Windsor PM · Clin Oncol (R Coll Radiol) 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
Bolger JJ, Dearnaley DP, Kirk D, et al. · Semin Oncol 1993 · Clinical Trial, Comparative Study
- A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone.
McEwan AJ, Amyotte GA, McGowan DG, et al. · Eur Urol 1994 · Clinical Trial, Comparative Study
- The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases.
Kasalický J, Krajská V · Eur J Nucl Med 1998 · Clinical Trial
- Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
Porter AT, McEwan AJ · Semin Oncol 1993 · Clinical Trial, Multicenter Study
Sponsor: Q Biomed
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.